351456-45-6 Usage
General Description
5-CHLORO-3-IODO-1H-INDAZOLE is a chemical compound with the molecular formula C7H4ClIN. It belongs to the class of indazole compounds and is characterized by a five-membered ring structure. This chemical is notable for its chlorine and iodine substituents, making it useful in various chemical reactions and organic synthesis. It has potential applications in pharmaceuticals, agrochemicals, and materials science. Its unique structure and properties make it a valuable building block for the synthesis of novel compounds with potential biological activities. However, its specific uses and applications may vary depending on the specific field and research focus.
Check Digit Verification of cas no
The CAS Registry Mumber 351456-45-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,5,1,4,5 and 6 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 351456-45:
(8*3)+(7*5)+(6*1)+(5*4)+(4*5)+(3*6)+(2*4)+(1*5)=136
136 % 10 = 6
So 351456-45-6 is a valid CAS Registry Number.
InChI:InChI=1/C7H4ClIN2/c8-4-1-2-6-5(3-4)7(9)11-10-6/h1-3H,(H,10,11)
351456-45-6Relevant articles and documents
SMAC MIMETICS USED AS IAP INHIBITORS AND USE THEREOF
-
Sheet 0104; 0105, (2020/12/10)
Disclosed are a class of SMAC mimetics used as IAP inhibitors, and in particular disclosed are compounds as shown in formula (I), isomers thereof, and pharmaceutically acceptable salts thereof. The IAP inhibitors are drugs for treating cancers, in particu
THERAPEUTIC INHIBITORY COMPOUNDS
-
Paragraph 00178, (2019/01/08)
Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds which are complement factor D inhibitors. Such compounds are useful for treating complement related disorders including, but are not limited to, autoimmune, inflammatory, and neurodegenerative diseases.
New CRTh2 antagonists.
-
Paragraph 0198, (2013/03/26)
The present invention relates to compounds of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.
